Cargando…

New insights on CRISPR/Cas9-based therapy for breast Cancer

CRISPR/Cas9 has revolutionized genome-editing techniques in various biological fields including human cancer research. Cancer is a multi-step process that encompasses the accumulation of mutations that result in the hallmark of the malignant state. The goal of cancer research is to identify these mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabit, Hussein, Abdel-Ghany, Shaimaa, Tombuloglu, Huseyin, Cevik, Emre, Alqosaibi, Amany, Almulhim, Fatma, Al-Muhanaa, Afnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082964/
https://www.ncbi.nlm.nih.gov/pubmed/33926574
http://dx.doi.org/10.1186/s41021-021-00188-0
_version_ 1783685938175541248
author Sabit, Hussein
Abdel-Ghany, Shaimaa
Tombuloglu, Huseyin
Cevik, Emre
Alqosaibi, Amany
Almulhim, Fatma
Al-Muhanaa, Afnan
author_facet Sabit, Hussein
Abdel-Ghany, Shaimaa
Tombuloglu, Huseyin
Cevik, Emre
Alqosaibi, Amany
Almulhim, Fatma
Al-Muhanaa, Afnan
author_sort Sabit, Hussein
collection PubMed
description CRISPR/Cas9 has revolutionized genome-editing techniques in various biological fields including human cancer research. Cancer is a multi-step process that encompasses the accumulation of mutations that result in the hallmark of the malignant state. The goal of cancer research is to identify these mutations and correlate them with the underlying tumorigenic process. Using CRISPR/Cas9 tool, specific mutations responsible for cancer initiation and/or progression could be corrected at least in animal models as a first step towards translational applications. In the present article, we review various novel strategies that employed CRISPR/Cas9 to treat breast cancer in both in vitro and in vivo systems.
format Online
Article
Text
id pubmed-8082964
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80829642021-04-30 New insights on CRISPR/Cas9-based therapy for breast Cancer Sabit, Hussein Abdel-Ghany, Shaimaa Tombuloglu, Huseyin Cevik, Emre Alqosaibi, Amany Almulhim, Fatma Al-Muhanaa, Afnan Genes Environ Review CRISPR/Cas9 has revolutionized genome-editing techniques in various biological fields including human cancer research. Cancer is a multi-step process that encompasses the accumulation of mutations that result in the hallmark of the malignant state. The goal of cancer research is to identify these mutations and correlate them with the underlying tumorigenic process. Using CRISPR/Cas9 tool, specific mutations responsible for cancer initiation and/or progression could be corrected at least in animal models as a first step towards translational applications. In the present article, we review various novel strategies that employed CRISPR/Cas9 to treat breast cancer in both in vitro and in vivo systems. BioMed Central 2021-04-29 /pmc/articles/PMC8082964/ /pubmed/33926574 http://dx.doi.org/10.1186/s41021-021-00188-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Sabit, Hussein
Abdel-Ghany, Shaimaa
Tombuloglu, Huseyin
Cevik, Emre
Alqosaibi, Amany
Almulhim, Fatma
Al-Muhanaa, Afnan
New insights on CRISPR/Cas9-based therapy for breast Cancer
title New insights on CRISPR/Cas9-based therapy for breast Cancer
title_full New insights on CRISPR/Cas9-based therapy for breast Cancer
title_fullStr New insights on CRISPR/Cas9-based therapy for breast Cancer
title_full_unstemmed New insights on CRISPR/Cas9-based therapy for breast Cancer
title_short New insights on CRISPR/Cas9-based therapy for breast Cancer
title_sort new insights on crispr/cas9-based therapy for breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082964/
https://www.ncbi.nlm.nih.gov/pubmed/33926574
http://dx.doi.org/10.1186/s41021-021-00188-0
work_keys_str_mv AT sabithussein newinsightsoncrisprcas9basedtherapyforbreastcancer
AT abdelghanyshaimaa newinsightsoncrisprcas9basedtherapyforbreastcancer
AT tombulogluhuseyin newinsightsoncrisprcas9basedtherapyforbreastcancer
AT cevikemre newinsightsoncrisprcas9basedtherapyforbreastcancer
AT alqosaibiamany newinsightsoncrisprcas9basedtherapyforbreastcancer
AT almulhimfatma newinsightsoncrisprcas9basedtherapyforbreastcancer
AT almuhanaaafnan newinsightsoncrisprcas9basedtherapyforbreastcancer